Colorectal CancerPhase 4PEGNCT00626054
Comparison of Two Methods of Administration of a PEG Solution
A Phase 4 study testing PEG solution in a single dose of 3 liters and PEG solution in people with Colorectal Cancer, run by Rabin Medical Center at 1 site in Israel.
Trial summary
The purpose of this study is to compare the effectiveness (quality of bowel cleansing) and ease of use (patient satisfaction) of two methods of administration of a precolonoscopy PEG solution in hospitalized patients. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Colorectal Cancer
- What is being tested?
- PEG solution in a single dose of 3 liters and PEG solution
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteIsrael
- Study dates
- Mar 2009to Mar 2012
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-80 years
- ability to understand and complete the questionnaires
- ability to participate in all stages of the research
Who cannot join
- Previous colon surgery
- endoscopic procedures under full anesthesia
- known sensitivity to the PEG solution
- terminal renal or cardiac insufficiency
- inability to sign the informed consent form
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of Two Methods of Administration of a PEG Solution During Bowel Preparation for Colonoscopy in Hospitalized Patients
The purpose of this study is to compare the effectiveness (quality of bowel cleansing) and ease of use (patient satisfaction) of two methods of administration of a precolonoscopy PEG solution in hospitalized patients.
Read the detailed description
Background and rationale of the research
Colonoscopy is an endoscopic examination whereby the physician can visually inspect the interior lining of the colon. It is the most efficient and accurate means of identifying, either directly or by biopsy, neoplasms in the large intestine and inflammatory processes, infections, or ischemia involving the whole colon and the distal small intestines. In addition, during the procedure, certain endoscopic treatments may be performed, such as removal of precancerous polyps and cauterization of bleeding sites such as vascular malformations by electrocoagulation.
Proper preparation of the bowel prior to colonoscopy is crucial to the quality of the examination. Suboptimal preparation can adversely affect the ability of the examiner to detect abnormalities in the small and large intestine or to carry out various endoscopic treatments. In some cases, poor preparation may necessitate canceling the procedure and rescheduling the patient for a repeated test.
To properly clear the bowel, patients must strictly adhere to a special diet and drink a laxative solution as directed. The physician selects the specific type of laxative solution from among those that are currently available on the basis of the patient's age and underlying diseases. At present, polyethylene glycol (PEG), owing to its good safety profile and relative lack of complications, is recommended in older patients (65 years or more), patients with hypertension or renal or cardiac insufficiency, and patients being treated with diuretics and ACE inhibitors. However, a major disadvantage of PEG is its difficulty of use, which involves bad taste and drinking 3 liters within a short period of time on the day before the examination.
Several recent studies in the medical literature have reported that in ambulatory patients, dividing the oral laxative solution into 2 doses taken at different times is more effective than drinking the whole amount in one session. On the basis of these findings, and given that the quality of the bowel preparation is known to be poorer in hospitalized than in ambulatory patients, we sought to determine if dividing the laxative dose will yield better results in hospitalized patients as well. It should be noted that laxative solutions constitute the most accepted method of preparing the bowel for colonoscopy and that in the present study, the sole difference from standard practice was the method of administration, namely a single or a split dose.
Aim of the study The purpose of this study is to compare the effectiveness (quality of bowel cleansing) and ease of use (patient satisfaction) of two methods of administration of a precolonoscopy PEG solution in hospitalized patients.
Method
Study design: Prospective, comparative, randomized
End points:
Primary - Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms Secondary - Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation.
Study sample: Four hundred hospitalized patients scheduled for a colonoscopy examination as part of their in-hospital work-up.
Inclusion criteria: Age 18-80 years; ability to understand and complete the questionnaires; ability to participate in all stages of the research.
Exclusion criteria: Previous colon surgery, previous endoscopic procedures under full anesthesia, known sensitivity to the PEG solution, terminal renal or cardiac insufficiency, inability to sign the informed consent form Colonoscopy: All patients will perform the precolonoscopy bowel preparation by one of two methods, according to the study design, followed by colonoscopy at the Gastrolenterology Institute of Rabin Medical Center
Questionnaires:
Demographic questionnaire - age, sex, weight, height, years of education Patient satisfaction questionnaire - ease of preparation and related symptoms In addition, physicians will rate the degree of bowel visibility after the procedure on a standard scale.
Study design:
The study sample will include hospitalized patients scheduled for colonoscopy. The physicians conducting the research will obtain informed consent from all candidates for the study prior to their enrollment.
At onset of the study, the participants will complete a demographic questionnaire in the presence of a member of the research team. Items will include age, sex, height, weight, and years of education.
Study participants will be randomly divided into 2 groups. Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test. Group 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test. The randomization will be performed at the Gastroenterology Institute. The secretary of the Institute will then inform the nurses/attendants in the various hospitalization departments which of the two procedures to apply to each individual patient. Before the procedure, the patients will complete a demographic questionnaire in the presence of a member of research team. The physician performing the colonoscopies will be blinded to the group allocation. After completing the colonoscopy, the physician will rate the quality of the bowel preparation in the patient's medical file according to the Aronchick scale, as follows:
Score Description 0 - excellent More than 95% of the intestines visible
- - good Large amount of transparent fluid requiring suction; more than 90% of intestines visible
- - fair Semisolid stool requiring suction/flushing; more than 90% of intestines visible
- - poor Semisolid stool difficult or impossible to remove; less than 90% of intestines visible
- - failed Repeated test required
Following the procedure, study participants will be asked to rate their satisfaction with the ease of use of the bowel preparation and the severity of symptoms related to it (e.g., stomach pain, nausea) on a VAS scale.
Colonoscopy method:
At the time of referral for colonoscopy, patients will receive a preliminary explanation of the test, of the alternative examinations currently available, and of any possible complications of the test. On the day of the colonoscopy, after receiving additional explanations from the attending gastroenterologist, patients will be asked to sign an informed consent form. The colonoscopy examination will be performed with patients lying on their left side; a sedative will be administered intravenously. During the procedure, the patient may feel cramping and discomfort from the infusion of air into the colon. The duration of the examination will about 30 minutes, depending on the structure of the colon, the amount of visibility consequent to the bowel preparation, and the degree of patient cooperation; the last two factors are essential for the success of the procedure. The endoscopic device will be carefully cleaned and sterilized between examinations in accordance with routine practice at our institute and accepted standards in developed countries.
Statistical analysis
On the basis of reported means and standard deviations in the medical literature, assuming a 75% compliance rate and type 1 error (α) of 0.05, a study sample of 400 hospitalized patients will yield a statistical power of more than 80%. The sample will be divided into two treatment groups using the computerized Research Randomizer 2007 (http://www.randomizer.org/) Independent t test will be used to compare means of continuous variables between the two groups, and chi-square test will be used to compare proportions. Nonparametric Mann-Whitney test will be used to analyze the level of preparation and bowel cleanliness, ranked on an ordinal scale, between the groups. All test will be two-sided; statistical significance will be set at p<0.05. All analyses will be performed with SPSS software, version 15.
Participating researchers
Gastroenterology Institute: Dr. Ram Dickman, Dr. Gal Eyal, Dr. Zvidi Ibrahim, Dr. Ofer Ben Bassat, Dr. Wilkin Alexander, Dr. Zohar Levy, Dr. Michal Cohen, Dr. Gerald Fraser, Prof. Yaron Niv, Dr. Boris Sapoznikov, Dr. Irit Avni-Biran, Nechama Horev, Melli Mor, Negba Segal, Shlomit Flaut, Yafit Honen, Igor Bogoslavsky, Ilana Morad.
Schedule
The study is planned for a two-year period:
Patient enrollment until mid-2009 Data collection and analysis until end 2008-beginning 2009
Ethics
Patient anonymity will be maintained.
- Conditions
- Colorectal Cancer
- Being tested
- PEG solution in a single dose of 3 liters, PEG solution
- Keywords
- Colonoscopy, PEG Solution
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PEG solution in a single dose of 3 litersDrug
Also called Meroken New
Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
PEG solutionDrug
Also called Meroken New
PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test. Receives: Drug: PEG solution in a single dose of 3 liters |
| 2 | Active comparator | Group 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test. Receives: Drug: PEG solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms
Measured: 1 year
Secondary outcomes (1)
Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Feb 2008 (estimated)
- Study startMar 2009
- Primary completionDec 2011
- Study completionMar 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 400 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rabin Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ram Dickman, Rabin Medical Center
- Investigators
- Yaron Niv, Prof, Study director, Rabin Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00626054
- Sponsor's protocol ID
- 004907
- Acronym
- PEG
- Status last verified
- Apr 2016
- First submitted
- 20 Feb 2008
- Last updated
- 13 Apr 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Two Methods of Administration of a PEG Solution During Bowel Preparation for Colonoscopy in Hospitalized Patients
- ClinicalTrials.gov ID
- NCT00626054
- Acronym / sponsor ID
- PEG / 004907
- Conditions
- Colorectal Cancer
- Keywords
- Colonoscopy, PEG Solution
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 400 participants (actual)
- Lead sponsor
- Rabin Medical CenterUniversity, hospital or other
- Study start
- Mar 2009
- Primary completion
- Dec 2011 (actual)
- Study completion
- Mar 2012 (actual)
- First posted
- 29 Feb 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the effectiveness (quality of bowel cleansing) and ease of use (patient satisfaction) of two methods of administration of a precolonoscopy PEG solution in hospitalized patients.
Detailed description
Background and rationale of the research
Colonoscopy is an endoscopic examination whereby the physician can visually inspect the interior lining of the colon. It is the most efficient and accurate means of identifying, either directly or by biopsy, neoplasms in the large intestine and inflammatory processes, infections, or ischemia involving the whole colon and the distal small intestines. In addition, during the procedure, certain endoscopic treatments may be performed, such as removal of precancerous polyps and cauterization of bleeding sites such as vascular malformations by electrocoagulation.
Proper preparation of the bowel prior to colonoscopy is crucial to the quality of the examination. Suboptimal preparation can adversely affect the ability of the examiner to detect abnormalities in the small and large intestine or to carry out various endoscopic treatments. In some cases, poor preparation may necessitate canceling the procedure and rescheduling the patient for a repeated test.
To properly clear the bowel, patients must strictly adhere to a special diet and drink a laxative solution as directed. The physician selects the specific type of laxative solution from among those that are currently available on the basis of the patient's age and underlying diseases. At present, polyethylene glycol (PEG), owing to its good safety profile and relative lack of complications, is recommended in older patients (65 years or more), patients with hypertension or renal or cardiac insufficiency, and patients being treated with diuretics and ACE inhibitors. However, a major disadvantage of PEG is its difficulty of use, which involves bad taste and drinking 3 liters within a short period of time on the day before the examination.
Several recent studies in the medical literature have reported that in ambulatory patients, dividing the oral laxative solution into 2 doses taken at different times is more effective than drinking the whole amount in one session. On the basis of these findings, and given that the quality of the bowel preparation is known to be poorer in hospitalized than in ambulatory patients, we sought to determine if dividing the laxative dose will yield better results in hospitalized patients as well. It should be noted that laxative solutions constitute the most accepted method of preparing the bowel for colonoscopy and that in the present study, the sole difference from standard practice was the method of administration, namely a single or a split dose.
Aim of the study The purpose of this study is to compare the effectiveness (quality of bowel cleansing) and ease of use (patient satisfaction) of two methods of administration of a precolonoscopy PEG solution in hospitalized patients.
Method
Study design: Prospective, comparative, randomized
End points:
Primary - Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms Secondary - Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation.
Study sample: Four hundred hospitalized patients scheduled for a colonoscopy examination as part of their in-hospital work-up.
Inclusion criteria: Age 18-80 years; ability to understand and complete the questionnaires; ability to participate in all stages of the research.
Exclusion criteria: Previous colon surgery, previous endoscopic procedures under full anesthesia, known sensitivity to the PEG solution, terminal renal or cardiac insufficiency, inability to sign the informed consent form Colonoscopy: All patients will perform the precolonoscopy bowel preparation by one of two methods, according to the study design, followed by colonoscopy at the Gastrolenterology Institute of Rabin Medical Center
Questionnaires:
Demographic questionnaire - age, sex, weight, height, years of education Patient satisfaction questionnaire - ease of preparation and related symptoms In addition, physicians will rate the degree of bowel visibility after the procedure on a standard scale.
Study design:
The study sample will include hospitalized patients scheduled for colonoscopy. The physicians conducting the research will obtain informed consent from all candidates for the study prior to their enrollment.
At onset of the study, the participants will complete a demographic questionnaire in the presence of a member of the research team. Items will include age, sex, height, weight, and years of education.
Study participants will be randomly divided into 2 groups. Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test. Group 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test. The randomization will be performed at the Gastroenterology Institute. The secretary of the Institute will then inform the nurses/attendants in the various hospitalization departments which of the two procedures to apply to each individual patient. Before the procedure, the patients will complete a demographic questionnaire in the presence of a member of research team. The physician performing the colonoscopies will be blinded to the group allocation. After completing the colonoscopy, the physician will rate the quality of the bowel preparation in the patient's medical file according to the Aronchick scale, as follows:
Score Description 0 - excellent More than 95% of the intestines visible
- - good Large amount of transparent fluid requiring suction; more than 90% of intestines visible
- - fair Semisolid stool requiring suction/flushing; more than 90% of intestines visible
- - poor Semisolid stool difficult or impossible to remove; less than 90% of intestines visible
- - failed Repeated test required
Following the procedure, study participants will be asked to rate their satisfaction with the ease of use of the bowel preparation and the severity of symptoms related to it (e.g., stomach pain, nausea) on a VAS scale.
Colonoscopy method:
At the time of referral for colonoscopy, patients will receive a preliminary explanation of the test, of the alternative examinations currently available, and of any possible complications of the test. On the day of the colonoscopy, after receiving additional explanations from the attending gastroenterologist, patients will be asked to sign an informed consent form. The colonoscopy examination will be performed with patients lying on their left side; a sedative will be administered intravenously. During the procedure, the patient may feel cramping and discomfort from the infusion of air into the colon. The duration of the examination will about 30 minutes, depending on the structure of the colon, the amount of visibility consequent to the bowel preparation, and the degree of patient cooperation; the last two factors are essential for the success of the procedure. The endoscopic device will be carefully cleaned and sterilized between examinations in accordance with routine practice at our institute and accepted standards in developed countries.
Statistical analysis
On the basis of reported means and standard deviations in the medical literature, assuming a 75% compliance rate and type 1 error (α) of 0.05, a study sample of 400 hospitalized patients will yield a statistical power of more than 80%. The sample will be divided into two treatment groups using the computerized Research Randomizer 2007 (http://www.randomizer.org/) Independent t test will be used to compare means of continuous variables between the two groups, and chi-square test will be used to compare proportions. Nonparametric Mann-Whitney test will be used to analyze the level of preparation and bowel cleanliness, ranked on an ordinal scale, between the groups. All test will be two-sided; statistical significance will be set at p<0.05. All analyses will be performed with SPSS software, version 15.
Participating researchers
Gastroenterology Institute: Dr. Ram Dickman, Dr. Gal Eyal, Dr. Zvidi Ibrahim, Dr. Ofer Ben Bassat, Dr. Wilkin Alexander, Dr. Zohar Levy, Dr. Michal Cohen, Dr. Gerald Fraser, Prof. Yaron Niv, Dr. Boris Sapoznikov, Dr. Irit Avni-Biran, Nechama Horev, Melli Mor, Negba Segal, Shlomit Flaut, Yafit Honen, Igor Bogoslavsky, Ilana Morad.
Schedule
The study is planned for a two-year period:
Patient enrollment until mid-2009 Data collection and analysis until end 2008-beginning 2009
Ethics
Patient anonymity will be maintained.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Drug: PEG solution in a single dose of 3 litersGroup 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test. |
| 2 | Active comparator | Drug: PEG solutionGroup 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age 18-80 years
- ability to understand and complete the questionnaires
- ability to participate in all stages of the research
Key exclusion criteria (5 listed)
- Previous colon surgery
- endoscopic procedures under full anesthesia
- known sensitivity to the PEG solution
- terminal renal or cardiac insufficiency
- inability to sign the informed consent form
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PEG solution in a single dose of 3 litersAlso: Meroken NewGroup 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test. | Drug | 1 |
| PEG solutionAlso: Meroken NewPEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test | Drug | 2 |
Primary outcome
Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms
Time frame: 1 year
1 secondary outcome
Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2016.
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yaron Niv, Prof study director
Rabin Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing PEG solution in a single dose of 3 liters and PEG solution in people with Colorectal Cancer, run by Rabin Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Apr 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2016.